For Our Patients


Clinical Trials and Research

Thank you for your interest in enrolling in one of our studies.

New patients interested in participating in a clinical trial and in enrolling to possibly receive the newest, most advanced treatment for their vitreoretinal conditions, with the care and attention from our professional clinical trial staff.

Currently Enrolling Studies

New patients interested in enrolling a study, please click on the Enroll in this Study to send us an email. Include your name, the reason of your interest in this study and the office location you receive treatment. You will receive a reply from us within 48 - 72 hours.

The following studies are currently available for enrollment.

For Central Florida Patients

Annexon

Study/Protocol Number: ANX007-GA-02 (Archer II)
Protocol Name: Archer II Treatment: IVT Indication: Geographic Atrophy
Title: A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)


Sponsor: EyeBiotech, Inc.

Protocol Number: EYE-Res-102
Protocol name: Brunello
Treatment: IVT
Indication: Diabetic Macular Degeneration


Sponsor: Eyepoint Pharmaceuticals

Protocol Number: EYP-1901-301
Protocol Name: Lugano
Treatment: IVT Insert
Indication: Wet AMD


Sponsor: Ocular Therapeutix

Protocol Number: OTX-TKI- 2023-AMD-303
Protocol Name: Sol-R
Treatment: Implant
Indication: Neovascular Age-Related macular Degeneration


Sponsor: Regeneron

Protocol Number: R3918-AMD-2326
Protocol Name: Sienna
Treatment: Subcutaneous Injection
Indication: Geographic Atrophy Secondary to Age-Related Macular Degeneration


Sponsor: RegenixBio

Protocol Number: RGX-314-3101
Protocol Name: Ascent
Treatment: Gene Therapy
Indicaton: nAMD


Sponsor: StealthBio Therapeutics, Inc.

Protocol Number: SPIAM-301
Protocol Name: ReNew
Treatment: Subcutaneous Injections Indication: Dry AMD



Enroll in a Study


Active Studies but Closed for Enrollment

Norse Eight Wet AMD treatment naïve

Aviceda GA secondary to AMD

QUASAR - Retinal Vein Occlusions


ASCENT - Wet Macular Degeneration


ELEVATUM - Diabetic Macular Edema


SHANGHAI HENLIUS for Wet Age-Related Macular Degeneration


New Day is for Diabetic Macula EDEMA


Pulsar WET MACULAR DEGENERATION


For North Florida Patients

Oculis Diamond for DME

Phase 2/3 double masked, Randomized, stage 2 Multicenter study of the Efficacy and Safety of OCS-01- Eye. Drops in Subjects with Diabetic Macular Edema


ANX007-GA-02 – Geographic Atrophy

A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled study of the Efficacy, safety, and tolerability of ANX007 Administered by Intravitreal Injection in patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)


Crimson / BI-1436-0007

A multicentre, randomized, sham-controlled, double masked, 72 week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy


KDK-1101-02

A Phase 2, Double-masked, Randomized, Sham-controlled, Multiple-dose Study of the Efficacy and Safety of Intravitreal KUS121 in the Treatment of Non-Arteritic Central Retinal Artery Occlusion (CRAO) – GION-


F. Hoffmann-La Roche Ltd-RIVOL1-CRVO BP44241

A PHASE Ib, multicenter, randomized, double masked, active comparator-controlled study to investigate the biological activity, safety, tolerability, pharmacokinetics and pharmacodynamics of RO7200394 in participants with macular edema secondary to central retinal vein occlusion.


DRCR-Protocol AF- Non-Proliferative Diabetic Retinopathy

A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening.


DRCR-Protocol AO- Home OCT vs Treat and Extend Study

Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO)




Enroll in a Study


Active Studies but Closed for Enrollment

Norse Eight Wet AMD treatment naïve


Pulsar WET MACULAR DEGENERATION


SHANGHAI HENLIUS FOR WET AMD


DRCR- Protocol AM- Epiretinal Membranes


Genentech, Inc – Magic ML43601- NPDR


ONL Therapeutics, Inc. (Retinal Detachment)


DRCR-Protocol AJ- Macula Hole



For more information about clinical trials or if you should have any questions, please feel free to contact us.